Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical setbacks for toll-like receptor 9 agonists in cancer

Cancer failures are not deterring interest in toll-like receptor agonists for other high profile indications.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Author information

Authors and Affiliations


Related links

Related links

Related links in Nature Research

Toll-like receptor therapies compete to reduce side effects

Web links

Coley Pharmaceutical

Idera Pharmaceuticals




Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schmidt, C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 25, 825–826 (2007).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing